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Asthma is a chronic inflammatory disease of the 
lung1, hypothetically caused by autoreactive Th2 
cells, whereas Th1 and regulatory T cells may be 
protective2. The role of specific T cells and their 
cytokines in allergic asthma is now well known3. 
Allergic asthma starts with influx of naive CD4+ T 
cells and eosinophils into the bronchial mucosa. 
The priming of the naïve CD4+ T cells to 
differentiate into proinflammatory Th2 cells - 
instead of the infection-fighting Th1 cells - by 
allergen activated dendritic cells (DCs) is an 
important proposed mechanism in occurrence of 
asthma4. Tregs have been implicated in playing a 
key role as immune negative regulators and key 
inducers of immune tolerance to inhaled allergens5.  
 
The development of Th subpopulations is 
dependent on the expression of Treg transcription 
factors2.  Foxp3 is transcription factor (Foxp3) 
predominantly expressed by CD4+ CD25+ Treg 
cells, and may correlates with the suppressive 
activity of these cells6. The discovery of FOXP3 as 
a specific marker of Treg-cell7 has recently led to 
an explosion of research in the biological properties 
of these T-cells which may open novel therapeutic 
strategies aimed at the induction of FOXP3 to 
convert conventional CD4+ T-cell to reverse 
aberrant Th2-mediated allergic asthmatic response8. 
So, this study aimed at investigating Treg FOXP3 
expression in childhood asthma and its relation to 
corticosteroid therapy. 
Original article 
Background: T cells are considered the main cells responsible for 
production of suppressive cytokines, and play a key role in balancing the 
immune responses to maintain the peripheral tolerance against 
allergens.  
Objective: The present study investigates T regulatory (Treg) forkhead-
winged helix protein 3 FOXP3 expression in childhood asthma and its 
relation to corticosteroid therapy.  
Methods: In this case control study, Treg FOXP3 was measured in blood 
of 60 children using real time polymerase chain reaction (RT-PCR) 
technique. Two asthmatic groups were included, one on corticosteroid 
therapy (20 patients) and the other not on corticosteroid treatment (20 
patients). They were compared to 20 healthy children as controls.  
Results: FOXP3 concentration was significantly elevated in asthmatic 
patients (90 ± 77.4) compared to healthy children (12.844 ± 10.6) (p= 
0.000). FOXP3 was significantly more elevated in asthmatics on 
corticosteroids (161.158 ± 63.9) than steroid naive asthmatics (36.038 ± 
23.4) (p=0.000). Levels of Treg FOXP3 in asthmatics with inhaled 
corticosteroids (mean 151.16 ± 53.79) were almost similar to FOXP3 in 
asthmatics with systemic corticosteroids (161.49±72.5) (p>0.05). FOXP3 
levels did not differ with smoking, asthma severity or disease control and 
did not correlate with age, FEV1, blood lymphocytes percentage or 
eosinophils percentage.  
Conclusion: Asthmatics have increased expression of FOXP3, and 
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METHODS 
This case control study was conducted on total 60 
Egyptian children; 40 asthmatic children who 
attended Chest Clinic, Children's Hospital, Ain 
Shams University from October 2010 to February 
2011 and 20 normal children (control subjects). 
Informed written consents were taken from all 
participants' parents. The study was approved by 
the local Ethics Committees.  The initial diagnosis 
and grading of bronchial asthma was made in the 
presence of typical asthma manifestations, and 
presence of reversible obstructive pattern on 
spirometry9 as recorded in the patient's file.  
Detailed medical history including asthma 
symptoms, details of corticosteroid treatment were 
obtained from patient's recording files. Chest 
examination (chest deformity, chest movement, air 
entry, wheezes, and additional sounds) was done to 
exclude the possibility of other causes of wheezy 
chest like cystic fibrosis, interstitial pulmonary 
disease, and others. Complete blood picture with 
differential count was done using cell counter 
(Coulter T660; Miami, USA). 
Spirometry was performed using MIR 
spirobank, which is a multifunction pocket 
spirometer that can operate as a stand-alone pocket 
spirometer or connected with a personal computer. 
Parameters obtained from such spirobank included; 
forced vital capacity (FVC), forced expiratory 
volume in the 1st second (FEV1), and FEV1% 
(FEV1/FVC X 100). Data were corrected to 
patient's age, sex, weight and height. Obtained 
values of FEV1 and FEV1% were used to correlate 
the current FEV1% with blood levels of FOXP3 
and to judge level of asthma control9. 
Asthmatics were allocated into 2 groups. 
Group A: included 20 asthmatic children (8 males 
and 12 females) with mean age 7.3±3.02 years (age 
range; 5 - 13 years) receiving regular corticosteroid 
(CS) inhalation therapy. Group B: included 20 
children (15 males and 5 females) with mean age 
6.25±1.77 years (age range 5 - 11) not on CS 
treatment. In addition, Group C included 20 
matched healthy children (11 males and 9 females) 
with a mean age of 7.00±1.76 years (age range 6 - 
11) enrolled as a control group. 
 Exclusion criteria included; children with any 
other chronic chest disease (cystic fibrosis, 
interstitial lung disease, congenital or 
developmental lung malformations) and children 
below 5 years (unable to perform spirometry).  
 
Assessment of FOXP3 concentration  
Samples: Lymphocytes were separated from 
heparinized blood samples and were processed and 
analyzed by multiplex RT-PCR analysis for semi-
quantitative PCR analysis of FOXp3 gene 
expression, relative β actin gene expression. Total 
RNA was extracted according to TriFast™ Total 
RNA Purification Kits, based on a modified salt 
precipitation procedure in combination with highly 
effective inhibitors of RNase activity (PeQLab 
Biotechnologie GmbH Corporation, Erlangen, 
Germany). Semi-quantitative Multiplex RT-PCR 
was done on 2g RNA from each sample using 
FOXp3 and β actin Primers. RNA was converted to 
cDNA using QIAGEN One Step RT-PCR Kit 
(QIAGEN, USA), Using FOXp3 primers 25  pm/ul 
: Sense primer: 5'-CCC ACT TAC AGG CAC TCC 
TC-3', and antisense primer 5'-CTT CTC CTT CTC 
CAG CAC CA-3'10. Housekeeping β actin primers 3 
pm/ul: The sequences of these primers were chosen 
according to Smith11. First step of RT was at 60˚ C 
for 60 minutes, PCR activation was at 95˚ C for 15 
minutes, then repeated 40 cycles of; denaturation at 
95˚ C for 1 minute, annealing at 50˚ C for 1 
minutes,  extension at 72˚ C for 1 minutes and final 
extension at 72˚ C for 10 minutes. β actin products 
bands were used as reference bands for the semi-
quantization of the FOXp3 RNA bands12. FOXP3 




The data were expressed as mean  standard 
deviation. Two-tailed unpaired t test was used to 
test the difference between different groups, where 
p<0.05 was considered statistically significant. All 
statistical analysis was performed with the software 
package SPSS for Windows, version 15.0 (SPSS 
Inc., Chicago,, Illinois). 
 
RESULTS 
Among group A (patients), family history of atopy 
was positive in 55% and 60% of these patients were 
passive smokers. According to GINA guidelines9; 
25% of them had mild asthma, 25% had moderate 
asthma and 50% had severe asthma; the mean value 
of FEV1% was 79.75 +5.03; 45% were well 
controlled and had FEV 1 > 80%. The mean values 
for blood eosinophil and lymphocyte percentage of 
the total leucocytic count were 5.65+2.99 and 
41.9+14.8 respectively.   
Among group B, family history of atopy was 
positive in 45%; 75% of these patients were passive 
smokers. All had mild asthma, the mean value of 
FEV1% was 83.65 +3.71; 90% were well controlled 
and had FEV 1 > 80%. The mean values for blood 
eosinophil and lymphocyte percentage of the total 
leucocytic count were 6.15+3.11 and 32.52+12.55 
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respectively. Treg FOXP3 concentration was 
significantly higher in asthmatic patients (90 ± 
77.4) compared to healthy controls (12.844 ± 10.6) 
(p<0.000) (table 2). Treg FOXP3 concentration in 
steroid naïve asthmatics (36.038 ± 23.4) was 
significantly higher compared to controls (12.844 ± 
10.6) (p= 0.007) and it was more elevated in 
asthmatics on regular C.S (161.158 ± 63.9) 
(p<0.000) (table 3). Route of corticosteroid intake 
(whether inhaled or systemic) did not affect the 
concentrations of FOXP3 significantly. FOXP3 
with inhaled corticosteroids (mean 151.16±53.79) 
was almost similar to FOXP3 with systemic 
corticosteroids (161.49±72.5) (p>0.05) (table 4). 
FOXP3 levels did not differ with passive smoking, 
disease severity, or disease control (p>0.05). 
FOXP3 was not correlated to age, FEV1 %, blood 




Table 1. Clinical and laboratory data of enrolled subjects. 
 



















Family history of asthma 10 (50%) 11 (55%) - 





























FOXP3 concentration% 161.158 ± 63.9 36.038 ± 23.4 12.844 ± 10.6 
FEV1% 79.75 +5.03 83.65 +3.71 - 
Lymphocytes % 
Eosinophils % 










Table 2. FOXP3 concentration % among asthmatics (Group A+Group B) 
versus control (Group C). 
 
FOXP3 % Mean ± SD Median Range P 
Group A+Group B  (n = 40) 90 ± 77.4 34.5 12.2 - 229  
0.000 Group C (n = 20) 12.844 + 10.6 32.6087 4.57-38.51 




Table 3.  FOXP3 concentration % among Group A, B and Group C. 
 
FOXP3% Group A 
(n = 20) 
Group B 
(n = 20) 
Group C  
(n = 20) 
P value 
A vs B 
P value 
A vs C 
P value 















SD= standard deviation 
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Table 4. FOXP3 concentration % among Group A regarding route of administration of corticosteroid 
treatment. 
 
FOXP3% Patients on  
inhaled C.S 
(n =15) 
Patients on  




Mean±SD 151.16 ± 53.79 161.49 ± 72.5 0.308   
(NS) Median (Range) 150 (28.91 -229.17) 160 (30.65 - 229.17) 





In our study, FOXP3 concentration was 
significantly elevated in asthmatic patients 
compared to healthy controls (p= 0.000). Moreover, 
Foxp3 levels were significantly higher in asthmatic 
group receiving corticosteroids than the steroid 
naïve group. FOXP3 may be a natural anti-
inflammatory secreted by Treg as an intrinsic body 
defense in hyperimmune states like bronchial 
asthma. One of the anti- inflammatory mechanisms 
exerted by the most ever known anti-inflammatory 
agent - which is cortisol- may be through FOXP3 
production.  Similarly Hori et al.13 stated that 
FOXP3 was highly expressed in CD4+CD25+ Treg 
cells in asthmatics and they explained their finding 
that FOXP3 acts as anti-inflammatory agent in 
asthma. In their opinion, decreased Foxp3 
expression causes immune disease by subverting 
the suppressive function of Treg cells and 
converting Treg cells into effector cells. Also, Wan 
and coworkers14 reported increased FOXP3 gene 
expression in all asthmatics as a defense mechanism 
expressed by Treg cells against the inflammatory 
process occurring in asthma.  
In contrast; Karengiannidis et al.15 found no 
significant difference in FOXP3 level in both 
healthy and asthmatics. However, they agreed with 
our study in elucidating the upregulatory role of 
corticosteroids on Treg FOXP3.   They recorded 
increased Treg activity and FOXP3 mRNA in 
unstimulated peripheral blood CD41 T cells of 
asthmatic patients treated with glucocorticoids, but 
not in patients with untreated asthma. In addition, 
they reported tight correlation between FOXP3 
expression and IL10 mRNA expression, which is a 
well-known anti-inflammatory cytokine in 
bronchial asthma. Another study done by Piccirillo 
et al.16 reported that there is increased expression of 
suppressive cytokines and transcription factor 
FOXP3 by Treg in response to corticosteroid 
treatment. The results of the present study revealed 
that FOXP was significantly increased in asthmatic 
patients receiving inhaled corticosteroid treatment, 
or systemic corticosteroid treatment, or both with 
no significant difference between them. 
Karengiannidis et al.15, Gemoungesaeth et al.17 and 
Kagoshima et al.18 found increased FOXP3 level in 
asthmatic patients on CS with no significant 
correlation to the dose or route of treatment. 
No data were found in the previous studies 
concerning the effect of clinical variables and other 
asthma medications on Treg FOXP3 expression. 
Our study revealed that Treg FOXP3 levels were 
not affected by or correlated to age, exposure to 
environmental tobacco smoke, disease control, 
asthma severity, lymphocyte percentage, eosinophil 
percentage or FEV1%. This finding may suggest 
that; expression of Treg FOXP3 in asthmatic 
patients is exclusively related to and affected by 
asthma pathogenesis and corticosteroid 
pharmacogenetic effects on Tregs. Karengiannidis 
et al.15 investigated correlation between FOXP3 
mRNA expression and many variables.  They 
reported no difference in FOXP3 mRNA expression 
between asthmatic patients with moderate and 
severe disease, intrinsic and extrinsic cause. They 
also found no relation of FOXP3 expression to the 
microsatellite genotypes, which were described to 
be associated with type I diabetes19. They found 
only serum IgE levels to be correlated with FOXP3 
expression, possibly because of the concomitant 
effect of glucocorticoids.  Although Matsumoto et 
al.20 emphasized the role of lung 
Foxp3+CD4+CD25+ T cells in the regulation of 
asthma phenotypes through an IL-10-mediated 
mechanism, they found no significant correlation 
between the frequency of Foxp3+CD4+CD25+ T 
cells and asthma severity.  
Finally most of the studies including ours 
support that asthmatics express FOXP3 more than 
healthy, and corticosteroid therapy whatever - its 
route -markedly enhances FOXP3 expression. Thus, 
corticosteroid treatment is considered not only 
immunosuppressive and anti-inflammatory agent, 
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but also promotes or initiates differentiation 
towards TR1 cells (suppressive Treg) by a FOXP3-
dependent mechanism. Therefore, strategies that 
convert transient glucocorticoid-induced Treg 
activity into a stable phenotype might improve 
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